LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

Revvity Inc

Geschlossen

BrancheGesundheitswesen

104.73 -0.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

104.39

Max

105.09

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.6M

47M

Verkäufe

-21M

699M

KGV

Branchendurchschnitt

54.418

79.874

EPS

0.4

Dividendenrendite

0.28

Gewinnspanne

6.675

Angestellte

11,000

EBITDA

-14M

181M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.24% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.28%

2.31%

Nächstes Ex-Dividendendatum

16. Jan. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

976M

12B

Vorheriger Eröffnungskurs

105.6

Vorheriger Schlusskurs

104.73

Nachrichtenstimmung

By Acuity

24%

76%

68 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Nov. 2025, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. Nov. 2025, 15:32 UTC

Akquisitionen, Fusionen, Übernahmen

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. Nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. Nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. Nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. Nov. 2025, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. Nov. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. Nov. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. Nov. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. Nov. 2025, 15:41 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. Nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. Nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. Nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. Nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. Nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. Nov. 2025, 11:07 UTC

Ergebnisse

Genting: Positive About Prospects Over Longer Term

27. Nov. 2025, 11:06 UTC

Ergebnisse

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: International Travel Demand Expected to Remain Resilient

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Global Growth Expected to Remain Subdued

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. Nov. 2025, 10:59 UTC

Ergebnisse

Genting Bhd 3Q Net Profit Fell 86% on Year

27. Nov. 2025, 10:58 UTC

Ergebnisse

Genting Bhd 3Q Rev Rose 14% on Year

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q Net MYR30.3M

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q EPS MYR0.0079

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

5.24% Vorteil

12-Monats-Prognose

Durchschnitt 111.1 USD  5.24%

Hoch 125 USD

Tief 100 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Stimmung

By Acuity

68 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat